We have updated our Terms of Use.
Please read our new Privacy Statement before continuing.

Capital transfusion

13 July 2020 By John Foley

Merging with a cash-shell run by former Citi banker Michael Klein gives the healthcare payment company a quick listing, $2 bln of cash and a partial exit for buyout firm Hellman & Friedman. It’s more expensive than a conventional IPO, but improves on that process in several ways.

This content is for Subscribers only

 

Email a friend

Please complete the form below.

Required fields *

*
*
*

(Separate multiple email addresses with commas)